Merck and Adagene ink trial collaboration and supply agreement

  • Merck KGaA (NYSE:MRK) and Adagene (NASDAQ:ADAG) have entered into the clinical trial collaboration and supply agreement.
  • Agreement includes two open-label, dose escalation and expansion clinical studies to evaluate Adagene's anti-CTLA-4 monoclonal antibody ((mAb)) product candidates, ADG116 and ADG126, in combination with Merck KGaA 's Keytruda for patients with advanced/metastatic solid tumors.
  • "Although we believe that ADG116 and ADG126 have great promise as single agents, combining with KEYTRUDA may unleash the potential of dual PD-1/CTLA-4 blockade...," CEO Peter Luo said.

    Over the current book year the total revenue from the company in Kenilworth will be 46.94 billion USD (consensus estimates). This is slightly lower than 2021's revenue of 47.99 billion USD.

    Historical revenues and results Merck KGaA & Co plus estimates 2021

    aandeel

    The analysts expect for 2021 a net profit of 14 billion USD. For this year the consensus of the result per share is a profit of 5.53 USD. The price-earnings-ratio equals 13.67.

    Huge dividend Merck KGaA & Co

    For this year the analysts expect a dividend of 2.55 USD per share. Thus the dividend yield equals 3.37 percent. The average dividend yield of the pharmaceutical companies is a moderate 1.36 percent.

    Based on the current number of shares Merck KGaA & Co's market capitalization equals 191.92 billion USD. 1

    Historical stock prices Merck KGaA & Co period 2007-2021

    fundamental research merck&co

    On Thursday the stock closed at 75.59 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.